Immuron Ltd — Director's Dealing 2018

Jul 30, 2018

==> picture [199 x 56] intentionally omitted <==

Appendix 3X – Initial Directors Interest Notice

Melbourne, Australia, July 31, 2018: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated pathogens, releases the Appendix 3X for Mr Richard Jay Berman for his appointment as Director as announced on 26 June 2018.

The late lodgement of the Appendix 3X was a result of an internal procedural oversight and have been picked up as part of the periodic internal review procedure. The delay was not caused by any oversight or action on the part of the director.

As stated in the earlier announcement on 26 June 2018, the Company agrees to issue 2 million unlisted options exercisable at A$0.50 per option on or before 30 June 2020 to Mr. Berman, subject to shareholder approval.

The Company considers that the procedures it has in place with its directors are adequate to enable compliance with the relevant obligations.

Yours sincerely,

==> picture [63 x 49] intentionally omitted <==

Phillip Hains Company Secretary

==> picture [591 x 62] intentionally omitted <==

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name	of	entity Immuron Limited
ABN		80 063 114 045

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Jay Berman
Date of appointment	01 July 2018

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

2,000,000* unlisted options exercisable at A$0.50 per option on or before 30 June 2020

*issuance of these securities is subject to receipt of shareholder approval at the Company’s next shareholder meeting.

• See chapter 19 for defined terms.

11/3/2002

Appendix 3X Page 1

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Number & class of Securities Note: Provide details of the circumstances giving rise to the relevant interest. Nil Nil

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
No. and class of securities to which interest relates	n/a

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002